MeiraGTx Secures $200 Mln From Hologen For Phase 3 Dvpt. Of AAV-GAD, Establish Neuro-AI JV

(RTTNews) - MeiraGTx Holdings plc. (MGTX), a clinical-stage, vertically integrated genetic medicines company, on Thursday, announced a broad strategic collaboration with Hologen Ltd., a Canadian cloud-based talent management solutions company. The deal is expected to close in the second quarter of 2025.

MeiraGTx will receive $200 million in upfront cash at closing and will be partnering with Hologen to create a joint venture called Hologen Neuro AI Ltd. The joint venture will result in the first neuro-AI clinical drug development company.

In addition to the $200 million payment, Hologen will provide up to $230 million in committed funding to support the development of AAV-GAD for Parkinson's disease through commercialization. The funding will also support early-stage clinical programs in the central nervous system, including AAV-BDNF for genetic obesity.

MeiraGTx will own 30 percent of the Hologen Neuro AI joint venture and will oversee clinical development and manufacturing. It will also sign exclusive agreements to supply the joint venture with clinical and commercial manufacturing.

MeiraGTx's AAV-GAD program for Parkinson's disease is ready for Phase 3, with commercial manufacturing already in progress.

In the pre-market trading, MeiraGTx is 12.79% higher at $7.23 on the Nasdaq.